清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials

医学 他汀类 随机对照试验 内科学 入射(几何) 荟萃分析 相对风险 临床试验 置信区间 物理疗法 光学 物理
作者
Jane Armitage,Colin Baigent,Elizabeth H Barnes,D. J. Betteridge,Lisa Blackwell,Michael A. Blazing,Louise Bowman,Eugene Braunwald,Robert Byington,Christopher P. Cannon,Michael Clearfield,Helen M. Colhoun,Rory Collins,Björn Dahlöf,Kelly Davies,Barry R. Davis,James A. de Lemos,John R. Downs,Paul N. Durrington,Jonathan Emberson
出处
期刊:The Lancet [Elsevier BV]
卷期号:393 (10170): 407-415 被引量:794
标识
DOI:10.1016/s0140-6736(18)31942-1
摘要

Background Statin therapy has been shown to reduce major vascular events and vascular mortality in a wide range of individuals, but there is uncertainty about its efficacy and safety among older people. We undertook a meta-analysis of data from all large statin trials to compare the effects of statin therapy at different ages. Methods In this meta-analysis, randomised trials of statin therapy were eligible if they aimed to recruit at least 1000 participants with a scheduled treatment duration of at least 2 years. We analysed individual participant data from 22 trials (n=134 537) and detailed summary data from one trial (n=12 705) of statin therapy versus control, plus individual participant data from five trials of more intensive versus less intensive statin therapy (n=39 612). We subdivided participants into six age groups (55 years or younger, 56–60 years, 61–65 years, 66–70 years, 71–75 years, and older than 75 years). We estimated effects on major vascular events (ie, major coronary events, strokes, and coronary revascularisations), cause-specific mortality, and cancer incidence as the rate ratio (RR) per 1·0 mmol/L reduction in LDL cholesterol. We compared proportional risk reductions in different age subgroups by use of standard χ 2 tests for heterogeneity when there were two groups, or trend when there were more than two groups. Findings 14 483 (8%) of 186 854 participants in the 28 trials were older than 75 years at randomisation, and the median follow-up duration was 4·9 years. Overall, statin therapy or a more intensive statin regimen produced a 21% (RR 0·79, 95% CI 0·77–0·81) proportional reduction in major vascular events per 1·0 mmol/L reduction in LDL cholesterol. We observed a significant reduction in major vascular events in all age groups. Although proportional reductions in major vascular events diminished slightly with age, this trend was not statistically significant (p trend =0·06). Overall, statin or more intensive therapy yielded a 24% (RR 0·76, 95% CI 0·73–0·79) proportional reduction in major coronary events per 1·0 mmol/L reduction in LDL cholesterol, and with increasing age, we observed a trend towards smaller proportional risk reductions in major coronary events (p trend =0·009). We observed a 25% (RR 0·75, 95% CI 0·73–0·78) proportional reduction in the risk of coronary revascularisation procedures with statin therapy or a more intensive statin regimen per 1·0 mmol/L lower LDL cholesterol, which did not differ significantly across age groups (p trend =0·6). Similarly, the proportional reductions in stroke of any type (RR 0·84, 95% CI 0·80–0·89) did not differ significantly across age groups (p trend =0·7). After exclusion of four trials which enrolled only patients with heart failure or undergoing renal dialysis (among whom statin therapy has not been shown to be effective), the trend to smaller proportional risk reductions with increasing age persisted for major coronary events (p trend =0·01), and remained non-significant for major vascular events (p trend =0·3). The proportional reduction in major vascular events was similar, irrespective of age, among patients with pre-existing vascular disease (p trend =0·2), but appeared smaller among older than among younger individuals not known to have vascular disease (p trend =0·05). We found a 12% (RR 0·88, 95% CI 0·85–0·91) proportional reduction in vascular mortality per 1·0 mmol/L reduction in LDL cholesterol, with a trend towards smaller proportional reductions with older age (p trend =0·004), but this trend did not persist after exclusion of the heart failure or dialysis trials (p trend =0·2). Statin therapy had no effect at any age on non-vascular mortality, cancer death, or cancer incidence. Interpretation Statin therapy produces significant reductions in major vascular events irrespective of age, but there is less direct evidence of benefit among patients older than 75 years who do not already have evidence of occlusive vascular disease. This limitation is now being addressed by further trials. Funding Australian National Health and Medical Research Council, National Institute for Health Research Oxford Biomedical Research Centre, UK Medical Research Council, and British Heart Foundation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
dianeil发布了新的文献求助10
2秒前
12秒前
amiee发布了新的文献求助10
18秒前
somehgo的应助被betsydouglas14采纳,获得30
24秒前
共享精神的应助被ping采纳,获得10
26秒前
包容的初阳完成签到,获得积分10
32秒前
35秒前
激动的忆翠完成签到,获得积分10
40秒前
风趣馒头完成签到,获得积分10
48秒前
48秒前
无私的碧玉完成签到,获得积分10
51秒前
俭朴迎荷完成签到,获得积分10
52秒前
1分钟前
n01W97的应助被科研通管家采纳,获得70
1分钟前
null的应助被科研通管家采纳,获得10
1分钟前
null的应助被科研通管家采纳,获得10
1分钟前
怕黑靖荷完成签到,获得积分10
1分钟前
专一的思菱完成签到,获得积分10
1分钟前
1分钟前
欢呼亦绿完成签到,获得积分10
1分钟前
ping发布了新的文献求助10
1分钟前
文静飞松完成签到,获得积分10
2分钟前
喜悦的紫雪完成签到,获得积分10
2分钟前
故意的白风完成签到,获得积分10
2分钟前
要减肥的菀完成签到,获得积分10
2分钟前
矢思然完成签到,获得积分10
3分钟前
蓝意完成签到,获得积分0
3分钟前
null的应助被科研通管家采纳,获得10
3分钟前
null的应助被科研通管家采纳,获得10
3分钟前
cocolinfly完成签到 ,获得积分10
3分钟前
null的应助被科研通管家采纳,获得10
3分钟前
Maestro_S的应助被科研通管家采纳,获得10
3分钟前
烂漫的诗蕊完成签到,获得积分10
3分钟前
快乐的如曼完成签到 ,获得积分10
3分钟前
淡淡傲柔完成签到,获得积分10
3分钟前
欣慰怀梦完成签到,获得积分10
4分钟前
漂亮忆曼完成签到,获得积分10
4分钟前
不如看海完成签到 ,获得积分10
4分钟前
Imran完成签到,获得积分10
4分钟前
霸气一斩完成签到,获得积分10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185411
求助须知:如何正确求助?哪些是违规求助? 9574140
关于积分的说明 21834375
捐赠科研通 7782865
什么是DOI,文献DOI怎么找? 3434552
关于科研通互助平台的介绍 2558842
邀请新用户注册赠送积分活动 2481280